SCHEMBL954287

SCHEMBL954287

Cc1nn2ccsc2c1-c1nc(OCc2ccccc2)c(C(=O)O)s1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.39
KDM4E B2RXH2 4/20 0.38
ALDH1A1 P00352 2/20 0.38
MCL1 Q07820 1/20 0.37
BAK1 Q16611 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
KMT2A Q03164 2/20 0.35
ALKBH1 Q13686 2/20 0.35
SCD O00767 1/20 0.35
RAB9A P51151 2/20 0.35
ATP4A P20648 1/20 0.35
ATP4B P51164 1/20 0.35
TSHR P16473 1/20 0.35
MEN1 O00255 1/20 0.35
TARBP2 Q15633 1/20 0.34
KDM5A P29375 1/20 0.34
KDM4C Q9H3R0 1/20 0.34
NPC1 O15118 1/20 0.34
GAA P10253 2/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL954278 0.92 CDC7 (0.36) SMN1; SMN2ALDH1A1MCL1BAK1L3MBTL1
SCHEMBL952330 0.92 TSHR (0.44) SMN1; SMN2KDM4EALDH1A1L3MBTL1KMT2A
SCHEMBL951849 0.84 SMN1; SMN2 (0.40) SMN1; SMN2KDM4EALDH1A1MCL1BAK1
SCHEMBL3784513 0.82 TRPM8 (0.50) SMN1; SMN2KDM4EALDH1A1KMT2ARAB9A
Bromide SCHEMBL956775 0.81 TRPM8 (0.49) SMN1; SMN2KDM4EALDH1A1KMT2ARAB9A
SCHEMBL954223 0.79 CDC7 (0.48) SMN1; SMN2KDM4EALDH1A1KMT2ARAB9A
SCHEMBL953424 0.79 TSHR (0.39) SMN1; SMN2KDM4EALDH1A1L3MBTL1KMT2A
SCHEMBL12918268 0.79 ALDH1A1 (0.34) KDM4EALDH1A1L3MBTL1ATP4AATP4B
SCHEMBL953848 0.78 L3MBTL1 (0.33) KDM4EALDH1A1L3MBTL1KMT2AATP4A
SCHEMBL954065 0.77 PLK1 (0.41) SMN1; SMN2ALDH1A1L3MBTL1KMT2ASCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9139589-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-09-22 US disclosed
US-9090601-B2 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-07-28 US disclosed
EP-2391619-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS Millennium Pharmaceuticals, Inc. (US) 2011-12-07 EP disclosed
US-20110003807-A1 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
US-20110003806-A1 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
WO-2010090716-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003807-A1 Thiazole derivatives MTOR, RICTOR, AKT2 SMN1; SMN2 3758/4885KDM4E 1981/4885ALDH1A1 1687/4885
US-20110003806-A1 Heteroaryls and uses thereof RICTOR, MTOR, AKT1S1 SMN1; SMN2 3959/4885KDM4E 2304/4885ALDH1A1 728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.